These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12034259)

  • 1. Rituximab treatment for posttransplantation lymphoproliferative disorder after small bowel transplantation.
    Nishida S; Kato T; Burney T; Levi D; Nery J; Madariaga J; Mittal N; Weppler D; Ruiz P; Tzakis A
    Transplant Proc; 2002 May; 34(3):957. PubMed ID: 12034259
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab in the treatment of pediatric small bowel transplant patients with posttransplant lymphoproliferative disorder unresponsive to standard treatment.
    McGhee W; Mazariegos GV; Sindhi R; Abu-Elmagd K; Reyes J
    Transplant Proc; 2002 May; 34(3):955-6. PubMed ID: 12034258
    [No Abstract]   [Full Text] [Related]  

  • 3. CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab.
    Ifthikharuddin JJ; Mieles LA; Rosenblatt JD; Ryan CK; Sahasrabudhe DM
    Am J Hematol; 2000 Oct; 65(2):171-3. PubMed ID: 10996837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab and rapamycin for posttransplant lymphoproliferative disease treatment: report of three cases.
    Garcia VD; Bonamigo-Filho JS; Neumann J; Fogliatto L; Gaiger AM; Garcia CD; Barros V; Keitel E; Bittar AE; Santos AF; Roithmann S
    Transplant Proc; 2002 Nov; 34(7):2993-5. PubMed ID: 12431680
    [No Abstract]   [Full Text] [Related]  

  • 5. Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kidney transplant recipient with posttransplant lymphoproliferative disease.
    Pham PT; Wilkinson AH; Gritsch HA; Pham PC; Miller JM; Lassman CR; Danovitch GM
    Transplant Proc; 2002 Jun; 34(4):1178-81. PubMed ID: 12072308
    [No Abstract]   [Full Text] [Related]  

  • 6. Post-transplant lymphoproliferative disorder treated with rituximab: case report.
    Meng HT; Li Y; Liu JH; Xu GX; Teng XD
    Chin Med J (Engl); 2007 May; 120(9):841-3. PubMed ID: 17531130
    [No Abstract]   [Full Text] [Related]  

  • 7. Usefulness and limitations of rituximab in managing patients with lymphoproliferative disorder after heart transplantation.
    Senechal M; Demers S; Cantin B; Bourgault C; Leblanc MH; Morin J; Couture C
    Exp Clin Transplant; 2012 Oct; 10(5):513-8. PubMed ID: 22747415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication.
    Verschuuren EA; Stevens SJ; van Imhoff GW; Middeldorp JM; de Boer C; Koëter G; The TH; van Der Bij W
    Transplantation; 2002 Jan; 73(1):100-4. PubMed ID: 11792987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center.
    Jain AB; Marcos A; Pokharna R; Shapiro R; Fontes PA; Marsh W; Mohanka R; Fung JJ
    Transplantation; 2005 Dec; 80(12):1692-8. PubMed ID: 16378063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab as treatment of posttransplant lymphoproliferative disorder in patients who underwent small bowel/multivisceral transplantation: report of three cases.
    Codeluppi M; Cocchi S; Guaraldi G; Di Benedetto F; Bagni A; Pecorari M; Gennari W; Pinna AD; Gerunda GE; Esposito R
    Transplant Proc; 2005; 37(6):2634-5. PubMed ID: 16182770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders presented as interstitial pneumonia; successful recovery with rituximab.
    Kunitomi A; Arima N; Ishikawa T
    Haematologica; 2007 Apr; 92(4):e49-52. PubMed ID: 17562592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
    Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
    Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
    Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
    Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation.
    Lee JJ; Lam MS; Rosenberg A
    Ann Pharmacother; 2007 Oct; 41(10):1648-59. PubMed ID: 17848421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation?
    Oertel SH; Anagnostopoulos I; Bechstein WO; Liehr H; Riess HB
    Transplantation; 2000 Feb; 69(3):430-2. PubMed ID: 10706055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of intraocular post-transplant lymphoproliferative disorder with intravenous rituximab.
    Iu LP; Yeung JC; Loong F; Chiang AK
    Pediatr Blood Cancer; 2015 Jan; 62(1):169-72. PubMed ID: 25174958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody therapy for posttransplant lymphoproliferative disorders.
    Habermann TM
    Liver Transpl; 2000 Sep; 6(5):657-8. PubMed ID: 10980069
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful treatment with rituximab of an Epstein-Barr virus-associated leiomyosarcoma occurring after liver transplantation.
    Jericho H; Weinstein J; Melin-Aldana H; Leuer KC; Wyers M; Alonso EM; Ekong UD
    J Pediatr Gastroenterol Nutr; 2014 Jan; 58(1):e2-4. PubMed ID: 24378523
    [No Abstract]   [Full Text] [Related]  

  • 19. Colonic perforation after rituximab treatment for posttransplant lymphoproliferative disorder.
    Kutsch E; Kreiger P; Consolini D; Furuya KN
    J Pediatr Gastroenterol Nutr; 2013 Jun; 56(6):e41. PubMed ID: 22395186
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab.
    O'Dwyer ME; Launder T; Rabkin JM; Nichols CR
    Leuk Lymphoma; 2000 Oct; 39(3-4):411-9. PubMed ID: 11342323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.